Illumina (NASDAQ:ILMN – Free Report) had its price target reduced by Piper Sandler from $195.00 to $185.00 in a research note released on Monday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the life sciences company’s stock.
A number of other equities analysts have also recently commented on ILMN. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com started coverage on shares of Illumina in a report on Thursday, August 29th. They set a “buy” rating for the company. Scotiabank decreased their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Finally, TD Cowen raised their price objective on shares of Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $164.00.
Check Out Our Latest Stock Analysis on Illumina
Illumina Stock Down 2.7 %
Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The company’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.33 EPS. Equities analysts predict that Illumina will post 4.11 EPS for the current year.
Institutional Trading of Illumina
Large investors have recently made changes to their positions in the stock. Empowered Funds LLC boosted its stake in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after purchasing an additional 66 shares during the last quarter. Caprock Group LLC grew its stake in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after acquiring an additional 83 shares during the period. UMB Bank n.a. raised its holdings in Illumina by 7.0% in the 2nd quarter. UMB Bank n.a. now owns 1,341 shares of the life sciences company’s stock valued at $140,000 after acquiring an additional 88 shares during the last quarter. Integrated Advisors Network LLC lifted its stake in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Finally, Moors & Cabot Inc. boosted its holdings in shares of Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after purchasing an additional 95 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.
Illumina Company Profile
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Stories
- Five stocks we like better than Illumina
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick
- 3 Best Fintech Stocks for a Portfolio Boost
- Mouse Rising: The Iger Investment Pays Off for Disney Investors
- When to Sell a Stock for Profit or Loss
- Can CAVA Stock Be the Next Chipotle? Earnings Can Help
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.